Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota key to variability in statin response
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota key to variability in statin response
Gastroenterology

Gut microbiota key to variability in statin response

Drug interaction
Gastroenterology

Today, 25%-30% of people over the age of 40-50 in Europe and the United States take statins. However, variability between patients in their response to treatment remains a challenge for clinicians. Can the characteristics of patients’ gut microbiota help us predict and manage this variability?

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail
Le microbiote intestinal, clé de la variabilité de la réponse aux statines

About this article

Created 19 September 2022
Updated 29 September 2022

Statins reduce the risk of atherosclerotic cardiovascular disease by inhibiting the activity of the 3-hydroxy-3-methylglutarate-coenzyme-A (HMG-CoA) reductase enzyme involved in the hepatic synthesis of low-density lipoprotein (LDL). Unfortunately, their effectiveness on LDL levels varies considerably among patients and adverse effects can occur, particularly insulin resistance, which increases the risk of type 2 diabetes mellitus. For physicians, determining the “maximum tolerated dose” for each patient based on the guidelines1 is often down to trial and error. However, this approach wastes time and can undermine patient compliance.

A blood marker to measure response to statins

Recent studies have already shown links between the gut microbiota and atherosclerotic cardiovascular risk, but also between the microbiota and statin use. Now US researchers2 have studied the gut flora’s role in responses to statins. By metabolizing statins, bacteria in the gut microbiota may modulate their bioavailability and potency to the host, or even contribute to their adverse effects. In a US cohort of 1,848 adults, 244 of whom were statin users, the researchers first validated a marker of statin response, plasma levels of the HMG-CoA reductase substrate, or HMG. HMG levels were found to be significantly higher in statin users than in non-users, and were negatively correlated with blood LDL levels in statin users only. The level of HMG reflected both the intensity of statin therapy and the presence of genetic variants in patients affecting their response to therapy.

Microbiota profile influences treatment efficacy and metabolic risk

The researchers then studied the association between statin efficacy as measured by HMG levels, the effect of statins on glucose control as measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score, and the composition of the gut microbiota, analyzed via 16S rRNA sequencing. They found that a more Bacteroides-enriched and diversity-depleted gut microbiome was associated with more intense statin responses, both in terms of efficacy and adverse effects on glucose control. However, a flora richer in Ruminococcaceae seemed to protect against the metabolic risk. These results were confirmed in a European cohort of 991 subjects whose gut microbiota was sequenced using a different method.

 

Towards precision statin therapies? 

 

This work not only explains variability in statin response, but also holds out the prospect of clinical tools to manage this variability. Indeed, plasma levels of HMG may supplement LDL levels as a source of information on treatment efficacy. Identifying the gut microbiota profile of patients may also allow us to predict responses to statins, to improve such responses using probiotics where necessary, and lastly, to propose to patients a more personalized treatment strategy for cardiovascular diseases.

Sources

1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255]. Eur Heart J. 2020;41(1):111-188

2. Wilmanski T, Kornilov SA, Diener C, et al. Heterogeneity in statin responses explained by variation in the human gut microbiome. Med (New York, N.Y.). 2022 Jun;3(6):388-405.e6

Tags
Statins Type 2 diabetes Insulin Metabolism Drug Drug interaction

en_view en_sources

    See also

    Can statins combat intestinal dysbiosis?
    When the bacteria in the intestinal microbiota store medicines
    Created 19 September 2022
    Updated 29 September 2022

    About this article

    To know more about this topic.

    Main topic

    Drug interaction

    Medical practice

    Gastroenterology

    Content type

    News
    Gastroenterology

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more

    Everything you need to know about Irritable Bowel Syndrome (IBS)

    Accrediting training, infographics, expert’s video, thematic folder, news… Biocodex Microbiota Institute pr...

    Find out more

    Gut Microbiota #17

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Gut Microbiota # 16

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Highlights from the UEGW

    By Dr. Lucas WautersGastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

    Find out more

    The Gut-Brain axis

    By Pr. Sarkis K. Mazmanian, John W. Bostick, Nadia SuryawinataBiology and Biological Engineering, Californi...

    Find out more

    Continue reading

    News
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    The psychobiotic diet: modulating gut microbiota to reduce stress
    13.02.2023

    The psychobiotic diet: modulating gut microbiota to reduce stress

    Read the article
    30.01.2023

    Schizophrenia and aggressive behavior: what involvement of the intestinal microbiota?

    Read the article
    23.01.2023

    Idiopathic urethritis in men: new infectious etiologies?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo